This is a report by a non-physician of a single case of LongCovid (also called Longhaulers or Chronic Covid or Post-Covid Syndrome) which was successfully treated. The main treatment component, to which the person with LongCovid attributes this success was ivermectin.

Covid-19

November, 2020, a young woman, about 20 years old, developed Covid-19. She had fever, cough, muscle and joint pains, severe fatigue, loss of smell and taste. She saw a physician and was not admitted to the hospital. She was diagnosed with Covid-19 by her symptoms. She was sent home, quarantined, and told to get plenty of rest and push fluids. She also took high doses of vitamin D (at least 10,000 IU/day).

LongCovid

After two weeks of Covid-19, and treatment only with OTC supplements, she no longer had fever, cough, or muscle/joint pains. Her sense of taste and smell returned. But a new set of symptoms emerged: brain fog, memory loss, fatigue, mood swings, and loss of appetite. These are common symptoms of LongCovid.

The memory loss was so bad, she would forget whole days or large portions of a day. The brain fog (difficulty concentrating) made it difficult to complete her schoolwork assignments in college. An assignment that usually would take a few hours now took a week. Tiredness made the brain fog worse. Her fatigue was severe, but she also had difficulty sleeping.

She began taking a number of supplements for Covid-19: Aspirin 325 mg once a day; Famotidine 20 mg twice a day, Melatonin, 9 mg before bed; riboflavin; Mirica Advanced (PEA and Luteolin); Vitamin D 10,000 IU once a day; Vitamin C – 500 mg twice a day; “Super K” (Vitamin K1 and K2) – once a day; Zinc (15 mg plus 1 mg copper) – two of these per day; Quercetin 250 mg 2x/day. The supplements definitely seemed to help, lessening her symptoms. But they did not seem curative.

She also had swollen lymph nodes in the morning. She used lymph drainage massage twice a day. That seemed to help significantly with the memory loss and brain fog. (Search YouTube for: lymph neck massage.) However, this is only a treatment for symptoms; it did not cure the LongCovid.

In late December, she took ivermectin, 12 mg on day one, none on day two or day three, the final second dose of 12 mg on day four. Within a few days, she reported improvement in memory, reduction in fatigue, and no significant brain fog or difficulty concentrating. A week and a half after the second dose of ivermectin, she reported that her symptoms were almost entirely gone, and she considered herself to be pretty much back to normal at that point in time (early January).

This was a remarkably fast resolution to a case of LongCovid. Her two-week bout with Covid-19 occurred in November, 2020. The LongCovid symptoms began in late November and lasted about six weeks beyond the end of her case of Covid-19. Ivermectin showed its effectiveness within days, with a near full return to normal in about 2 weeks from start of ivermectin treatment.

The dosing for ivermectin is found in the i-MASK protocol in the PDF file on this webpage. The dosing is based on body weight, with about 0.2 mg of ivermectin per kg of body weight (which is the same as 0.09 mg of ivermectin per pound of body weight). Only two doses are needed: first dose, skip a day, second dose. (The LongCovid patient described above skipped two days due to stomach irritation.)

Conclusion

Not every LongCovid patient can expect the same results for treatment with ivermectin. Also, some medications, illnesses, or conditions may contraindicate ivermectin. The reason that ivermectin worked in the case described in this article is perhaps due to viral persistence. But not every case of LongCovid has viral persistence. Some cases of LongCovid seem to be caused by inflammation and immune system dysregulation after the virus has cleared; such cases are perhaps more likely to respond to steroids than ivermectin.

In this particular case, there may have been Covid-19 virus (SARS-CoV-2) still active in her body, causing various symptoms, which appeared to be mainly neurological. The assumption that no SARS-CoV-2 virus remains in patients with LongCovid is imprudent. There are good reasons to believe that some cases of LongCovid are due to viral persistence. Therefore, I suggest that physicians consider using ivermectin for patients with LongCovid, so as to clear any virus that remains. Once that treatment is applied, whether successfully or unsuccessfully, subsequent interventions can be applied with greater certitude that the cause of the symptoms is not due to continued presence of the virus.

I hope this report is helpful. Keep in mind that this is only one example of LongCovid. This was not a formal medical study, and the author of this article is not a physician.

UPDATE

“Ivermectin in Post-COVID-19 Syndrome

“Increasing reports of persistent, vexing, and even disabling symptoms after recovery from acute COVID-19 have been reported and which many have termed the condition as “long Covid” and patients as “long haulers”, estimated to occur in approximately 10% of cases (77–79). Generally considered as a post-viral syndrome consisting of a chronic and sometimes disabling constellation of symptoms which include, in order, fatigue, shortness of breath, joint pains and chest pain. Many patients describe their most disabling symptom as impaired memory and concentration, often with extreme fatigue, described as “brain fog”, and are highly suggestive of the condition myalgic encephalomyelitis/chronic fatigue syndrome, a condition well-reported to begin after viral infections, in particular with Epstein-Barr virus. Although no specific treatments have been identified for long COVID, a recent manuscript by Aguirre-Chang et al from the National University of San Marcos in Peru reported on the experience with ivermectin in such patients (80). They treated 33 patients who were between 4 and 12 weeks from the onset of symptoms with escalating doses of ivermectin; 0.2mg/kg for 2 days if mild, 0.4mg/kg for 2 days if moderate, with doses extended if symptoms Review of the Emerging Evidence Supporting the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19 persisted. They found that in 87.9% of the patients, resolution of all symptoms was observed after two doses with an additional 7% reporting complete resolution after additional doses. Their experience suggests the need for controlled studies to better test efficacy in this vexing syndrome.” FLCCC Alliance, Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19 [1]

Ronald L Conte Jr
Covid.us.org
“an author, not a doctor”

1. Kory, Pierre, G. Umberto Meduri, Jose Iglesias, Joseph Varon, Keith Berkowitz, Howard Kornfeld, Eivind Vinjevoll, Mitchell Scott, Fred Wagshul, and Paul E. Marik. “Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19.” (2020).